-DOCSTART-	O

Title	O
:	O
Psychosocial	B-I
behaviour	I-I
management	I-I
programme	I-I
for	O
home	B-P
-	I-P
dwelling	I-P
people	I-P
with	I-P
dementia	I-P
:	O
A	O
cluster	O
-	O
randomized	O
controlled	O
trial	O
.	O

Little	O
is	O
known	O
about	O
the	O
effectiveness	O
of	O
a	O
psychosocial	O
behaviour	O
management	O
programme	O
on	O
home	O
-	O
dwelling	O
people	O
with	O
dementia	O
.	O

We	O
developed	O
a	O
Behaviour	O
Analytics	O
&	O
Support	O
Enhancement	O
(	O
BASE	O
)	O
programme	O
for	O
care	O
managers	O
and	O
professional	O
caregivers	O
of	O
home	O
care	O
services	O
in	O
Japan	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
BASE	O
on	O
challenging	O
behaviour	O
of	O
home	O
-	O
dwelling	O
people	O
with	O
dementia	O
.	O

METHODS	O
:	O
A	O
cluster	O
-	O
randomized	O
controlled	O
trial	O
was	O
conducted	O
with	O
home	O
care	O
providers	O
from	O
3	O
different	O
districts	O
in	O
Tokyo	O
.	O

Each	O
provider	O
recruited	O
persons	B-P
with	I-P
dementia	I-P
aged	I-P
65	I-P
years	I-P
or	I-P
older	I-P
to	I-P
receive	I-P
home	I-P
care	I-P
in	I-P
the	I-P
BASE	I-P
programme	I-P
in	I-P
August	I-P
2016	I-P
.	O

An	B-O
online	I-O
monitoring	I-O
and	O
assessment	B-O
system	I-O
was	O
introduced	O
to	O
the	O
intervention	O
group	O
for	O
repeated	O
measures	O
of	O
challenging	B-O
behaviour	I-O
with	O
a	B-O
total	I-O
score	I-O
of	I-O
the	I-O
Neuropsychiatric	I-O
Inventory	I-O
.	O

Care	O
professionals	O
in	O
both	O
the	O
intervention	O
and	O
control	O
groups	O
evaluated	O
challenging	O
behaviour	O
of	O
persons	O
with	O
dementia	O
at	O
baseline	O
(	O
September	O
2016	O
)	O
and	O
follow	O
-	O
up	O
(	O
February	O
2017	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
value	O
of	O
subtraction	B-I
MRI	I-I
in	O
detection	O
of	O
amyloid	O
-	O
related	O
imaging	O
abnormalities	O
with	O
oedema	O
or	O
effusion	O
in	O
Alzheimer	O
'	O
s	O
patients	O
:	O
An	O
interobserver	O
study	O
.	O

METHODS	O
:	O
We	O
included	O
75	B-P
AD	I-P
patients	I-P
receiving	I-P
bapineuzumab	I-P
treatment	I-P
,	I-P
including	I-P
29	I-P
ARIA	I-P
-	I-P
E	I-P
cases	I-P
.	O

Five	O
neuroradiologists	O
rated	O
their	O
brain	O
MRI	O
-	O
scans	O
with	B-I
and	O
without	B-I
subtraction	I-I
images	I-I
.	O

The	B-O
accuracy	I-O
of	I-O
evaluating	I-O
the	I-O
presence	I-O
of	I-O
ARIA	I-O
-	I-O
E	I-O
,	O
intraclass	B-O
correlation	I-O
coefficient	I-O
(	I-O
ICC	I-O
)	I-O
and	O
specific	B-O
agreement	I-O
was	O
calculated	O
.	O

-DOCSTART-	O

Title	O
:	O
Cross	O
-	O
Sectional	O
Associations	O
of	O
Total	B-I
Plasma	I-I
Homocysteine	I-I
with	O
Cortical	B-I
?	I-I
-	I-I
Amyloid	I-I
Independently	O
and	O
as	O
a	O
Function	O
of	O
Omega	O
3	O
Polyunsaturated	O
Fatty	O
Acid	O
Status	O
in	O
Older	B-P
Adults	I-P
at	I-P
Risk	I-P
of	I-P
Dementia	I-P
.	O

METHODS	O
:	O
This	O
is	O
a	O
cross	O
-	O
sectional	O
study	O
using	O
data	O
from	O
the	O
Multidomain	O
Alzheimer	O
Preventive	O
Trial	O
(	O
MAPT	O
)	O
;	O
a	O
randomised	O
controlled	O
trial	O
.	O

French	B-P
community	I-P
dwellers	I-P
aged	I-P
70	I-P
or	I-P
over	I-P
reporting	I-P
subjective	I-P
memory	I-P
complaints	I-P
,	I-P
but	I-P
free	I-P
from	I-P
a	I-P
diagnosis	I-P
of	I-P
clinical	I-P
dementia	I-P
.	O

Individuals	O
were	O
from	O
the	O
MAPT	O
trial	O
(	O
n	O
=	O
177	O
)	O
with	O
data	O
on	O
total	O
plasma	O
homocysteine	O
at	O
baseline	O
and	O
cortical	O
A?	O
load	O
.	O

Cortical	B-O
-	I-O
to	I-O
-	I-O
cerebellar	I-O
standard	I-O
uptake	I-O
value	I-O
ratios	I-O
were	O
assessed	O
using	O
[	B-O
18	I-O
F	I-O
]	I-O
florbetapir	I-O
positron	I-O
emission	I-O
tomography	I-O
(	I-O
PET	I-O
)	I-O
.	O

Total	B-O
baseline	I-O
plasma	I-O
homocysteine	I-O
was	O
measured	O
using	O
an	B-O
enzymatic	I-O
cycling	I-O
assay	I-O
.	O

Baseline	B-O
omega	I-O
3	I-O
index	I-O
was	O
measured	O
using	O
gas	B-O
chromatography	I-O
.	O

Cross	O
-	O
sectional	O
associations	O
were	O
explored	O
using	O
adjusted	O
multiple	O
linear	O
regression	O
models	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
phase	O
III	O
randomized	O
trial	O
of	O
gantenerumab	B-I
in	O
prodromal	O
Alzheimer	O
'	O
s	O
disease	O
.	O

METHODS	O
:	O
In	O
this	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
phase	O
III	O
study	O
,	O
we	O
investigated	O
gantenerumab	B-I
over	O
2	O
years	O
.	O

Patients	O
were	O
randomized	O
to	O
gantenerumab	B-I
105	O
mg	O
or	O
225	O
mg	O
or	O
placebo	B-C
every	O
4	O
weeks	O
by	O
subcutaneous	O
injection	O
.	O

The	O
primary	O
endpoint	O
was	O
the	O
change	O
from	O
baseline	O
to	O
week	O
104	O
in	O
Clinical	B-O
Dementia	I-O
Rating	I-O
Sum	I-O
of	I-O
Boxes	I-O
(	I-O
CDR	I-O
-	I-O
SB	I-O
)	I-O
score	I-O
.	O

We	O
evaluated	O
treatment	O
effects	O
on	O
cerebrospinal	B-O
fluid	I-O
biomarkers	I-O
(	O
all	O
patients	O
)	O
and	O
amyloid	B-O
positron	I-O
emission	I-O
tomography	I-O
(	O
substudy	O
)	O
.	O

A	O
futility	O
analysis	O
was	O
performed	O
once	O
50	O
%	O
of	O
patients	O
completed	O
2	O
years	O
of	O
treatment	O
.	O

Safety	O
was	O
assessed	O
in	O
patients	O
who	O
received	O
at	O
least	O
one	O
dose	O
.	O

-DOCSTART-	O

Title	O
:	O
Long	O
-	O
Lasting	O
Neuropsychological	O
Effects	O
of	O
a	B-I
Computerized	I-I
Cognitive	I-I
Training	I-I
in	O
Patients	B-P
Affected	I-P
by	I-P
Early	I-P
Stage	I-P
Alzheimer	I-P
'	I-P
s	I-P
Disease	I-P
:	O
Are	O
They	O
Stable	O
Over	O
Time	O
?	O
.	O

METHODS	O
:	O
Eighty	B-P
AD	I-P
patients	I-P
were	O
randomized	O
in	O
two	O
groups	O
and	O
underwent	O
a	B-I
computerized	I-I
cognitive	I-I
training	I-I
,	O
or	O
a	O
control	O
intervention	O
.	O

-DOCSTART-	O

Title	O
:	O
Delayed	O
-	O
Start	O
Analyses	O
in	O
the	O
Phase	O
3	O
Solanezumab	B-I
EXPEDITION3	O
Study	O
in	O
Mild	O
Alzheimer	O
'	O
s	O
Disease	O
.	O

METHODS	O
:	O
EXPEDITION3	O
was	O
a	O
Phase	O
3	O
,	O
double	O
-	O
blind	O
study	O
with	O
participants	O
randomized	O
to	O
solanezumab	B-I
(	O
400	O
mg	O
)	O
or	O
placebo	B-C
every	O
4	O
weeks	O
for	O
80	O
weeks	O
,	O
with	O
an	O
optional	O
extension	O
of	O
active	O
treatment	O
.	O

The	O
delayed	O
-	O
start	O
analysis	O
was	O
designed	O
to	O
determine	O
if	O
a	O
statistically	O
significant	O
treatment	O
difference	O
established	O
during	O
the	O
placebo	O
-	O
controlled	O
period	O
is	O
maintained	O
(	O
at	O
predefined	O
level	O
)	O
during	O
the	O
delayed	O
-	O
start	O
period	O
,	O
which	O
would	O
suggest	O
the	O
active	O
drug	O
has	O
a	O
disease	O
-	O
modifying	O
effect	O
.	O

The	O
delayed	O
-	O
start	O
analysis	O
was	O
assessed	O
across	O
multiple	O
efficacy	O
measures	O
,	O
and	O
includes	O
data	O
from	O
baseline	O
in	O
the	O
placebo	O
-	O
controlled	O
period	O
and	O
up	O
to	O
9	O
months	O
in	O
the	O
delayed	O
-	O
start	O
period	O
.	O

-DOCSTART-	O

Title	O
:	O
Effectiveness	O
of	O
Anti	B-I
-	I-I
Dementia	I-I
Drugs	I-I
in	O
Extremely	O
Severe	O
Alzheimer	O
'	O
s	O
Disease	O
:	O
A	O
12	O
-	O
Week	O
,	O
Multicenter	O
,	O
Randomized	O
,	O
Single	O
-	O
Blind	O
Study	O
.	O

METHODS	O
:	O
In	O
this	O
randomized	O
and	O
rater	O
-	O
blinded	O
trial	O
,	O
65	B-P
AD	I-P
patients	I-P
with	I-P
a	I-P
Mini	I-P
-	I-P
Mental	I-P
State	I-P
Examination	I-P
score	I-P
from	I-P
0	I-P
to	I-P
5	I-P
and	I-P
a	I-P
score	I-P
of	I-P
6	I-P
c	I-P
or	I-P
worse	I-P
on	I-P
Functional	I-P
Assessment	I-P
Staging	I-P
were	O
randomly	O
assigned	O
to	O
an	B-I
ADD	I-I
-	I-I
continuation	I-I
group	O
(	O
N	O
=	O
30	O
)	O
or	O
an	B-I
ADD	I-I
-	I-I
discontinuation	I-I
group	O
(	O
N	O
=	O
35	O
)	O
.	O

The	O
current	O
use	O
of	O
donepezil	O
or	O
memantine	O
was	O
maintained	O
for	O
12	O
weeks	O
in	O
the	B-I
ADD	I-I
-	I-I
continuation	I-I
group	O
and	O
was	O
discontinued	O
after	O
baseline	O
in	O
the	B-I
ADD	I-I
-	I-I
discontinuation	I-I
group	O
.	O

Efficacy	O
measures	O
were	O
obtained	O
at	O
baseline	O
and	O
12	O
weeks	O
.	O

The	O
primary	O
efficacy	O
variable	O
was	O
the	O
change	O
from	O
baseline	O
to	O
the	O
end	O
of	O
the	O
study	O
in	O
Baylor	B-O
Profound	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
BPMSE	I-O
)	I-O
scores	I-O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
Applicability	O
of	O
a	B-I
High	I-I
-	I-I
Intensity	I-I
Functional	I-I
Exercise	I-I
Program	I-I
Among	O
Older	B-P
People	I-P
With	I-P
Dementia	I-P
Living	I-P
in	I-P
Nursing	I-P
Homes	I-P
.	O

METHODS	O
:	O
The	O
Ume	O
Dementia	O
and	O
Exercise	O
study	O
,	O
a	O
cluster	O
-	O
randomized	O
controlled	O
trial	O
set	O
in	O
16	O
nursing	O
homes	O
in	O
Ume	O
,	O
Sweden	O
.	O

Ninety	B-P
-	I-P
three	I-P
people	I-P
with	I-P
dementia	I-P
(	I-P
mean	I-P
[	I-P
SD	I-P
]	I-P
Mini	I-P
-	I-P
Mental	I-P
State	I-P
Examination	I-P
score	I-P
of	I-P
15	I-P
.	I-P
4	I-P
[	I-P
3	I-P
.	I-P
4	I-P
]	I-P
)	I-P
were	O
randomized	O
to	O
the	B-I
exercise	I-I
intervention	I-I
.	O

Thirty	O
-	O
four	O
participants	O
had	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
and	O
59	O
non	O
-	O
Alzheimer	O
'	O
s	O
dementia	O
(	O
non	O
-	O
AD	O
)	O
.	O

High	B-I
-	I-I
Intensity	I-I
Functional	I-I
Exercise	I-I
(	I-I
HIFE	I-I
)	I-I
program	I-I
was	O
conducted	O
in	O
groups	O
of	O
3	O
to	O
8	O
participants	O
.	O

Two	O
physiotherapists	O
led	O
5	O
sessions	O
(	O
45	O
minutes	O
each	O
)	O
per	O
fortnight	O
for	O
4	O
months	O
(	O
total	O
40	O
sessions	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
Physical	B-I
Activity	I-I
in	O
Nursing	B-P
Home	I-P
Residents	I-P
with	I-P
Dementia	I-P
:	O
A	O
Randomized	O
Controlled	O
Trial	O
.	O

METHODS	O
:	O
Eighty	B-P
-	I-P
seven	I-P
nursing	I-P
home	I-P
residents	I-P
with	I-P
dementia	I-P
were	O
randomly	O
assigned	O
to	O
3	B-I
physical	I-I
activity	I-I
interventions	I-I
:	O
activities	B-I
of	I-I
daily	I-I
living	I-I
(	I-I
ADL	I-I
)	I-I
training	I-I
,	O
multicomponent	B-I
exercise	I-I
training	I-I
,	O
or	O
combined	B-I
multicomponent	I-I
exercise	I-I
and	O
ADL	B-I
training	I-I
.	O

Outcomes	O
were	O
measured	O
at	O
baseline	O
,	O
and	O
after	O
3	O
and	O
6	O
months	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
Precision	O
Medicine	O
Model	O
for	O
Targeted	B-I
NSAID	I-I
Therapy	I-I
in	O
Alzheimer	O
'	O
s	O
Disease	O
.	O

METHODS	O
:	O
Proteomic	B-O
assays	I-O
of	I-O
plasma	I-O
from	O
a	O
multicenter	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
parallel	O
group	O
trial	O
,	O
with	O
1	O
-	O
year	O
exposure	O
to	O
rofecoxib	B-I
(	O
25	O
mg	O
once	O
daily	O
)	O
,	O
naproxen	B-I
(	O
220	O
mg	O
twice	O
-	O
daily	O
)	O
or	O
placebo	B-C
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
Exercise	B-I
on	O
Drug	O
-	O
Related	O
Falls	O
Among	O
Persons	B-P
with	I-P
Alzheimer	I-P
'	I-P
s	I-P
Disease	I-P
:	O
A	O
Secondary	O
Analysis	O
of	O
the	O
FINALEX	O
Study	O
.	O

METHODS	O
:	O
In	O
the	O
FINALEX	O
trial	O
,	O
community	B-P
-	I-P
dwelling	I-P
persons	I-P
with	I-P
AD	I-P
received	O
either	O
home	B-I
-	I-I
based	I-I
or	O
group	B-I
-	I-I
based	I-I
exercise	I-I
twice	O
weekly	O
for	O
1	O
year	O
(	O
n	O
=129	O
)	O
;	O
the	O
control	O
group	O
received	O
normal	B-C
care	I-C
(	O
n	O
=65	O
)	O
.	O

The	O
number	O
of	O
falls	O
was	O
based	O
on	O
spouses	O
'	O
fall	O
diaries	O
.	O

We	O
examined	O
the	B-O
incidence	I-O
rate	I-O
ratios	I-O
(	I-O
IRRs	I-O
)	I-O
for	I-O
falls	I-O
among	O
both	O
non	O
-	O
users	O
and	O
users	O
of	O
various	O
FRDs	O
(	O
antihypertensives	O
,	O
psychotropics	O
,	O
drugs	O
with	O
anticholinergic	O
properties	O
[	O
DAPs	O
]	O
)	O
in	O
both	O
control	O
and	O
combined	O
intervention	O
groups	O
.	O

-DOCSTART-	O

Title	O
:	O
Probiotic	B-I
and	O
selenium	B-I
co	I-I
-	I-I
supplementation	I-I
,	O
and	O
the	O
effects	O
on	O
clinical	O
,	O
metabolic	O
and	O
genetic	O
status	O
in	O
Alzheimer	O
'	O
s	O
disease	O
:	O
A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
controlled	O
trial	O
.	O

METHODS	O
:	O
This	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
controlled	O
clinical	O
trial	O
was	O
conducted	O
among	O
79	B-P
patients	I-P
with	I-P
AD	I-P
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
selenium	B-I
(	O
200	O
?g	O
/	O
day	O
)	O
plus	O
probiotic	B-I
containing	O
Lactobacillus	B-I
acidophilus	I-I
,	O
Bifidobacterium	B-I
bifidum	I-I
,	O
and	O
Bifidobacterium	B-I
longum	I-I
(	O
2	O
	O
109	O
CFU	O
/	O
day	O
each	O
)	O
(	O
n	O
=	O
27	O
)	O
,	O
selenium	B-I
(	O
200	O
?g	O
/	O
day	O
)	O
(	O
n	O
=	O
26	O
)	O
or	O
placebo	B-C
(	O
n	O
=	O
26	O
)	O
for	O
12	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
a	B-I
Tailored	I-I
Lighting	I-I
Intervention	I-I
on	O
Sleep	O
Quality	O
,	O
Rest	O
-	O
Activity	O
,	O
Mood	O
,	O
and	O
Behavior	O
in	O
Older	B-P
Adults	I-P
With	I-P
Alzheimer	I-P
Disease	I-P
and	I-P
Related	I-P
Dementias	I-P
:	O
A	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
This	O
14	O
-	O
week	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
crossover	O
design	O
clinical	O
trial	O
administered	O
an	B-I
all	I-I
-	I-I
day	I-I
active	I-I
or	O
control	B-C
lighting	I-C
intervention	I-C
to	O
46	B-P
patients	I-P
with	I-P
ADRD	I-P
in	I-P
8	I-P
long	I-P
-	I-P
term	I-P
care	I-P
facilities	I-P
for	I-P
two	I-P
4	I-P
-	I-P
week	I-P
periods	I-P
(	I-P
separated	I-P
by	I-P
a	I-P
4	I-P
-	I-P
week	I-P
washout	I-P
)	I-P
.	O

The	O
study	O
employed	O
wrist	B-O
-	I-O
worn	I-O
actigraphy	I-O
measures	I-O
and	O
standardized	B-O
measures	I-O
of	I-O
sleep	I-O
quality	I-O
,	O
mood	B-O
,	O
and	O
behavior	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Long	O
-	O
term	O
safety	O
and	O
tolerability	O
of	O
atabecestat	B-I
(	I-I
JNJ	I-I
-	I-I
54861911	I-I
)	I-I
,	O
an	B-I
oral	I-I
BACE1	I-I
inhibitor	I-I
,	O
in	O
early	B-P
Alzheimer	I-P
'	I-P
s	I-P
disease	I-P
spectrum	I-P
patients	I-P
:	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
and	O
a	O
two	O
-	O
period	O
extension	O
study	O
.	O

METHODS	O
:	O
In	O
the	O
placebo	O
-	O
controlled	O
double	O
-	O
blind	O
parent	O
ALZ2002	O
study	O
,	O
participants	B-P
aged	I-P
50	I-P
to	I-P
85	I-P
years	I-P
were	O
randomized	O
(	O
1:1:1	O
)	O
to	O
placebo	B-C
or	O
atabecestat	B-I
10	O
or	O
50	O
mg	O
once	O
daily	O
(	O
later	O
reduced	O
to	O
5	O
and	O
25	O
mg	O
)	O
for	O
6	O
months	O
.	O

Participants	O
entered	O
ALZ2004	O
,	O
a	O
12	O
-	O
month	O
treatment	O
extension	O
with	O
placebo	B-C
or	O
atabecestat	B-I
10	O
or	O
25	O
mg	O
,	O
followed	O
by	O
an	O
open	O
-	O
label	O
phase	O
.	O

Safety	B-O
,	O
changes	O
in	O
CSF	B-O
biomarker	I-O
levels	I-O
,	O
brain	B-O
volume	I-O
,	O
and	O
effects	O
on	O
cognitive	B-O
performance	I-O
were	O
assessed	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
,	O
controlled	O
clinical	O
trial	O
of	O
plasma	B-I
exchange	I-I
with	O
albumin	B-I
replacement	I-I
for	O
Alzheimer	O
'	O
s	O
disease	O
:	O
Primary	O
results	O
of	O
the	O
AMBAR	O
Study	O
.	O

METHODS	O
:	O
Three	B-P
hundred	I-P
forty	I-P
-	I-P
seven	I-P
patients	I-P
(	I-P
496	I-P
screened	I-P
)	I-P
were	O
randomized	O
(	O
1:1:1	O
:	O
1	O
)	O
into	O
three	B-I
PE	I-I
treatment	I-I
arms	O
with	O
different	B-I
doses	I-I
of	I-I
albumin	I-I
and	O
intravenous	B-I
immunoglobulin	I-I
replacement	I-I
(	O
6	O
-	O
week	O
period	O
of	O
weekly	O
conventional	O
PE	O
followed	O
by	O
a	O
12	O
-	O
month	O
period	O
of	O
monthly	O
low	O
-	O
volume	O
PE	O
)	O
,	O
and	O
placebo	B-C
(	O
sham	O
)	O
.	O

